[Biological availability of potassium from a sustained release preparation].
The bioavailability of potassium from a sustained-release KC1 preparation has been compared in 10 healthy volunteers with that of a non-sustained-release KC1 coated tablet by means of urinary elimination data. From the 40 mEq KC1 additionally administered, 35.2 mEq (88%) and 35.5 mEq (88.8%) respectively were eliminated by the kidneys. On the evidence of this elimination data the sustained-release potassium preparation showed the same bioavailability as the non-sustained-release KC1 tablets. The retard form was excellently tolerated.
D001682:Biological Availability; D001702:Biopharmaceutics; D003692:Delayed-Action Preparations; D006801:Humans; D011188:Potassium / Q000008:administration & dosage* / Q000652:urine
D003692:Delayed-Action Preparations; D011188:Potassium
Die biologische Verfügbarkeit von Kalium aus einem Retardpräparat